The pathology and tissue resources core will represent a joint effort by the Department of Pathology, MD. Anderson Medical Center (MDACC) and the Simmons Cancer Center, UT Southwestern Medical Center (UTSWMC). It will provide specimens, pathology review, cell culture of selected specimens, specialized reagents and facilities in support of the other SPORE projects and investigators such as microdissection of defined cell populations and cultures of paired tumor-lymphoblastoid cell lines and preneoplastic specimens. While the primary purpose of the SPORE is to provide optimal materials and services in support of the research projects included in the SPORE proposal, data and materials will be made available to SPORE investigators at other institutions whenever possible.
The specific aims of the proposal are summarized as follows:
Aim 1, To provide pathological review of all clinical specimens utilized in the clinical and research projects outlined in the SPORE proposal. All clinical specimens (about 1500) will be reviewed by two surgical pathologists highly experienced in lung cancer (Drs Mackay and Gazdar), who will arrive at a consensus diagnosis. In cases of disagreement, Drs. Mackay and Gazdar will consult by phone, fax, Internet, or in person, and arrive at a consensus diagnosis.
Aim #2, Maintenance of a tissue repository of lung cancer specimens and adjacent non-malignant lung and bronchial epithelium. It is anticipated that 600 samples from 200 resections will be collected (about 70 resections per year).
Aim #3, Establish matched tumor and B lymphoblastoid cell lines from patients with lung cancer (about 50 pairs, of which 28 pairs have already been established). These will be used for the preparation of DNA, RNA and protein products from the matched samples, for use by SPORE investigators.
Aim #4, Prepare specialized materials and services for utilization by SPORE investigators, including preparation of nucleic acids and protein pellets, cryosections, microdissection of precisely identified lesions, and cultures of bronchial epithelium.
Aim #5, Maintain an on-line computerized listing of all specimens and procedures and patient demographics and pathological data. Data and specimens will be made available to investigators at other SPORE sites.
These aims will permit optimal utilization of the resources by SPORE investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA070907-03S1
Application #
6296129
Study Section
Project Start
1998-09-01
Project End
1999-08-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
3
Fiscal Year
1998
Total Cost
Indirect Cost
City
Dallas
State
TX
Country
United States
Zip Code
75390
Guo, Hou-Fu; Tsai, Chi-Lin; Terajima, Masahiko et al. (2018) Pro-metastatic collagen lysyl hydroxylase dimer assemblies stabilized by Fe2+-binding. Nat Commun 9:512
Meraz, Ismail M; Majidi, Mourad; Cao, Xiaobo et al. (2018) TUSC2 Immunogene Therapy Synergizes with Anti-PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic Kras-Mutant Mouse Lung Cancer Models. Cancer Immunol Res 6:163-177
Zhang, Liren; Lin, Jing; Ye, Yuanqing et al. (2018) Serum MicroRNA-150 Predicts Prognosis for Early-Stage Non-Small Cell Lung Cancer and Promotes Tumor Cell Proliferation by Targeting Tumor Suppressor Gene SRCIN1. Clin Pharmacol Ther 103:1061-1073
Bayo, Juan; Tran, Tram Anh; Wang, Lei et al. (2018) Jumonji Inhibitors Overcome Radioresistance in Cancer through Changes in H3K4 Methylation at Double-Strand Breaks. Cell Rep 25:1040-1050.e5
Ludlow, Andrew T; Wong, Mandy Sze; Robin, Jerome D et al. (2018) NOVA1 regulates hTERT splicing and cell growth in non-small cell lung cancer. Nat Commun 9:3112
Chen, Limo; Diao, Lixia; Yang, Yongbin et al. (2018) CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. Cancer Discov 8:1156-1175
Mender, Ilgen; LaRanger, Ryan; Luitel, Krishna et al. (2018) Telomerase-Mediated Strategy for Overcoming Non-Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance. Neoplasia 20:826-837
Gong, Ke; Guo, Gao; Gerber, David E et al. (2018) TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. J Clin Invest 128:2500-2518
Wang, Jacqueline F; Pu, Xingxiang; Zhang, Xiaoshan et al. (2018) Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing. Cancer 124:1061-1069
Pierzynski, Jeanne A; Ye, Yuanqing; Lippman, Scott M et al. (2018) Socio-demographic, Clinical, and Genetic Determinants of Quality of Life in Lung Cancer Patients. Sci Rep 8:10640

Showing the most recent 10 out of 1059 publications